BR0208593A - método para o tratamento de um mamìfero, composto, e, composição farmacêutica - Google Patents

método para o tratamento de um mamìfero, composto, e, composição farmacêutica

Info

Publication number
BR0208593A
BR0208593A BRPI0208593-3A BR0208593A BR0208593A BR 0208593 A BR0208593 A BR 0208593A BR 0208593 A BR0208593 A BR 0208593A BR 0208593 A BR0208593 A BR 0208593A
Authority
BR
Brazil
Prior art keywords
treatment
mammal
compound
pharmaceutical composition
compounds
Prior art date
Application number
BRPI0208593-3A
Other languages
English (en)
Inventor
Allan R Moorman
Romeo Romagnoli
Pier Giovanni Baraldi
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of BR0208593A publication Critical patent/BR0208593A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE UM MAMìFERO, COMPOSTO, E, COMPOSIçãO FARMACêUTICA". Novos compostos tiofeno fundido são providos e métodos para usar estes compostos para várias indicações terapêuticas. Os compostos da invenção são particularmente utilizáveis para o tratamento de dor neuropática.
BRPI0208593-3A 2001-03-30 2002-03-29 método para o tratamento de um mamìfero, composto, e, composição farmacêutica BR0208593A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28041601P 2001-03-30 2001-03-30
PCT/US2002/009943 WO2002083083A2 (en) 2001-03-30 2002-03-29 Pharmaceutically active compounds and methods of use

Publications (1)

Publication Number Publication Date
BR0208593A true BR0208593A (pt) 2006-02-21

Family

ID=23072979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208593-3A BR0208593A (pt) 2001-03-30 2002-03-29 método para o tratamento de um mamìfero, composto, e, composição farmacêutica

Country Status (15)

Country Link
US (2) US7101905B2 (pt)
EP (1) EP1383463B1 (pt)
JP (1) JP4303474B2 (pt)
KR (1) KR100888093B1 (pt)
AT (1) ATE506947T1 (pt)
AU (1) AU2002303191B2 (pt)
BR (1) BR0208593A (pt)
CA (1) CA2443135C (pt)
DE (1) DE60239864D1 (pt)
ES (1) ES2365905T3 (pt)
IL (2) IL158186A0 (pt)
MX (1) MXPA03008936A (pt)
NZ (1) NZ528635A (pt)
WO (1) WO2002083083A2 (pt)
ZA (1) ZA200308020B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2443135C (en) * 2001-03-30 2010-07-13 Allan R. Moorman Pharmaceutically active compounds and methods of use
TW200403991A (en) * 2002-04-11 2004-03-16 Smithkline Beecham Corp NF-κb inhibitors
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2014202765A1 (en) * 2013-06-21 2014-12-24 Lek Pharmaceuticals D.D. Preparation of chiral 1-methyl-2,3,4,5-1h-benzodiazepines via asymmetric reduction of alpha-substituted styrenes
TWI734699B (zh) * 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
CN116410205B (zh) * 2021-12-29 2024-07-05 上海皓元生物医药科技有限公司 一种3-取代-9-甲基-噻吩并三唑并噁嗪类化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401499D0 (sv) 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
EP0931074B1 (en) 1996-09-06 2003-05-07 Takeda Chemical Industries, Ltd. Condensed 4,5,6,7-tetrahydrobenzo c]thiophenes as enhancer for cell differentiation induction factor action
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
GB9808665D0 (en) * 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic compounds
CA2443135C (en) * 2001-03-30 2010-07-13 Allan R. Moorman Pharmaceutically active compounds and methods of use

Also Published As

Publication number Publication date
CA2443135C (en) 2010-07-13
EP1383463B1 (en) 2011-04-27
US7101905B2 (en) 2006-09-05
US20060183921A1 (en) 2006-08-17
EP1383463A2 (en) 2004-01-28
IL158186A (en) 2011-03-31
KR20040083335A (ko) 2004-10-01
US7449490B2 (en) 2008-11-11
NZ528635A (en) 2006-11-30
ZA200308020B (en) 2007-01-31
EP1383463A4 (en) 2009-03-25
WO2002083083A3 (en) 2003-11-06
ES2365905T3 (es) 2011-10-13
JP2005500994A (ja) 2005-01-13
US20030073733A1 (en) 2003-04-17
ATE506947T1 (de) 2011-05-15
DE60239864D1 (de) 2011-06-09
CA2443135A1 (en) 2002-10-24
KR100888093B1 (ko) 2009-03-11
WO2002083083A2 (en) 2002-10-24
IL158186A0 (en) 2004-03-28
AU2002303191B2 (en) 2007-01-18
MXPA03008936A (es) 2005-03-07
JP4303474B2 (ja) 2009-07-29

Similar Documents

Publication Publication Date Title
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
NO20035156L (no) Fremgangsmåter for brønnbehandling
IS8398A (is) Lyfjasamsetningar til að meðhöndla æxli
BR0306566B1 (pt) mÉtodo para fabricar escària contendo àxido de titÂnio.
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
DK1353668T3 (da) Fremgangsmåder til fremstillingen af farmaceutiske sammensætninger, der indeholder epothilonanaloger, til behandlingen af cancer
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
EE200300537A (et) Meetod madalaannuselise farmatseutilise kompositsiooni tootmiseks
PT1411926E (pt) Inibidores de integrina para o tratamento de doencas oftalmicas
DE60228484D1 (de) Cytotoxische mittel
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
BR0208593A (pt) método para o tratamento de um mamìfero, composto, e, composição farmacêutica
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
NO20042904L (no) Anvendelse av norepinefrin-reopptakinhibitorer for behandling av kognitiv svikt
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
IL159153A0 (en) Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
DK1434588T3 (da) 2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
ITGE20020050A0 (it) Procedimento per il trattamento di filati mediante agugliatura.
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
EP1436279A4 (en) CHEMICAL COMPOUNDS
DK1523985T3 (da) Ikke-radioaktivt strontiumholdigt middel til behandling af kræft

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K31/381, C07D 333/78, C07D 333/64, C07D 333/66, A61P 25/00, A61P 25/02, A61P 25/04

Ipc: A61K 31/381 (2011.01), C07D 333/78 (2011.01), C07D

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements